Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2015

Open Access 01-12-2015 | Research

Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline

Authors: Nazir A. Pala, Bashir A. Laway, Raiz A. Misgar, Rayees A. Dar

Published in: Diabetology & Metabolic Syndrome | Issue 1/2015

Login to get access

Abstract

Background

Hyperprolactinemia has been associated with changes in body composition and metabolic abnormalities. Normalization of prolactin (PRL) with dopamine agonists has been found to reverse these abnormalities. This study was designed to assess the anthropometric and metabolic alterations associated with prolactinoma and response of these abnormalities to cabergoline treatment.

Methods

In a non-randomised matched prospective design, 19 consecutive patients with prolactinoma (median PRL 118.6 (105.3) μg/L) and 20 controls were studied. The controls were age, gender and body mass index (BMI) matched. Anthropometric data and metabolic variables were studied at baseline, 3 and 6 months after cabergoline treatment.

Results

Patients with prolactinoma had increased level of fasting plasma glucose (P < .001), LDL-cholesterol (P = .001) and triglycerides (TG) (P = .009) as compared to age, gender and BMI matched healthy controls. There was a significant decrease of body weight at 3 months (P = .029), with a further decline at 6 months (P < .001) of cabergoline therapy. In addition, there was a significant decrement of BMI (P < .001), waist circumference (P = .003), waist-hip ratio (P = .03) and total body fat (P = .003) at 6 months of cabergoline treatment. A significant decline in plasma glucose (P < .001), total cholesterol (P = .009), LDL-cholesterol (P < .001) and TG (P < .001) was seen after 6 months of cabergoline treatment.

Conclusions

Patients with prolactinoma have adverse metabolic profile compared with matched controls. Normalization of PRL with cabergoline corrects all the metabolic abnormalities.
Literature
1.
Knudtzon J, Johansen PW, Haug E, Gautvik K. Effects of hypersecretion of growth hormone and prolactin on plasma levels of glucagon and insulin in GH3-cell tumor-bearing rats, and the influence of bromocriptine treatment. Life Sci. 1986;39:617–21.CrossRefPubMed
2.
Byatt JC, Staten NR, Salsgiver WJ, Kostelc JG, Collier RJ. Stimulation of food intake and weight gain in mature female rats by bovine prolactin and bovine growth hormone. Am J Physiol. 1993;264:E986–92.PubMed
3.
Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin and its receptor: actions signal transduction pathways and phenotypes observed in prolactin receptor knockout mice. Endocr Rev. 1998;19:225–68.CrossRefPubMed
4.
Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab. 2006;17:110–6.CrossRefPubMed
5.
Moore BJ, Gerardo-Gettens T, Horvitz BA, Stern JS. Hyperprolactinemia stimulates food intake in the female rat. Brain Res Bull. 1986;17:563–9.CrossRefPubMed
6.
Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary. 2009;12:96–104.CrossRefPubMed
7.
Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, et al. Dopaminergic tone and obesity: an insight from prolactinoma treated with bromocriptine. Eur J Endocrinol. 2002;147:77–84.CrossRefPubMed
8.
Gualillo O, Lago F, García M, Menéndez C, Señarís R, Casanueva FF, et al. Prolactin stimulates leptin secretion by rat white adipose tissue. Endocrinology. 1999;140:5149–53.PubMed
9.
Nilsson L, Binart N, Bohlooly-Y M, Bramnert M, Egecioglu E, Kindblom J, et al. Prolactin and growth hormone regulate adiponectin secretion and receptor expression in adipose tissue. Biochem Biophys Res Commun. 2005;331:1120–6.CrossRefPubMed
10.
Schmid C, Goede DL, Hauser RS, Brändle M. Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly. 2006;136:254–8.PubMed
11.
Serri O, Beauregard H, Rasio E, Hardy J. Decreased sensitivity to insulin in women with microprolactinomas. Fertil Steril. 1986;45:572–4.PubMed
12.
Maccario M, Grottoli S, Razzore P, Procopio M, Oleandri SE, Ciccarelli E, et al. Effects of glucose load and/or arginine on insulin and growth hormone secretion in hyperprolactinemia and obesity. Eur J Endocrinol. 1996;135:205–10.CrossRefPubMed
13.
Ling C, Svensson L, Odén B, Weijdegård B, Edén B, Edén S, et al. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab. 2003;88:1804–8.CrossRefPubMed
14.
Creemers LB, Zelissen PM, van`t Verlaat JW, Koppeschaar HP. Prolactinoma and body weight: a retrospective study. Acta Endocrinol. 1991;125:392–6.PubMed
15.
Galluzzi F, Salti R, Stagi S, La Cauza F, Chiarelli F. Reversible weight gain and prolactin levels—long-term follow-up in childhood. J Pediatr Endocrinol Metab. 2005;18:921–4.CrossRefPubMed
16.
LaPensee CR, Horseman ND, Tso P, Brandebourg TD, Hugo ER, Ben-Jonathan N. The prolactin-deficient mouse has an unaltered metabolic phenotype. Endocrinology. 2006;147:4638–45.CrossRefPubMed
17.
Masao K, Nobuo Y, Toshimasa O, Yoshio N, Paul Z, Shuji I. Criteria and classification of obesity in Japan and Asia-Oceania. Asia Pacific J Clin Nutr. 2002;11:S732–7.CrossRef
18.
Naliato EC, Violante AH, Caldas D, Lamounier Filho A, Loureiro CR, Fontes R, et al. Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clin Endocrinol. 2007;67:845–52.CrossRef
19.
Berinder K, Nystrom T, Hoybye C, Hall K, Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011;14:199–207.CrossRefPubMed
20.
Landgraf R, Landraf-Leurs MM, Weissmann A, Hörl R, von Werder K, Scriba PC. Prolactin: a diabetogenic hormone. Diabetologia. 1977;13:99–104.CrossRefPubMed
21.
Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S. Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest. 2003;26:341–6.CrossRefPubMed
22.
Bahceci M, Tuzcu A, Bahceci S, Tuzcu S. Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome? J Endocrinol Invest. 2003;26:655–9.CrossRefPubMed
23.
Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gözü H, Sezgin O, et al. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol. 2003;149:187–93.CrossRefPubMed
24.
Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin-secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol. 1998;48:547–53.CrossRef
25.
Pelkonen R, Nikkilä EA, Grahne B. Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol. 1982;16:383–90.CrossRef
26.
Heshmati HM, Turpin G, de Gennes JL. Chronic hyperprolactinemia and plasma lipids in women. Klin Wochenschr. 1987;65:516–9.CrossRefPubMed
27.
Fahy U, Hopton MI, Hartog M, Bolton CH, Hull MG. The lipoprotein profile of women with hyperprolactinaemic amenorrhoea. Hum Reprod. 1999;14:285–7.CrossRefPubMed
28.
Kok P, Roelfsema F, Frölich M, Frölich M, van Pelt J, Stokkel MP, et al. Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. Am J Physiol Endocrinol Metab. 2006;291:E1038–43.CrossRefPubMed
29.
Lachelin GC, Abu-fadil S, Yen SS. Functional delineation of hyperprolactinemic-amenorrhea. J Clin Endocrinol Metab. 1977;44:1163–74.CrossRefPubMed
30.
Nunes MC, Sobrinho LG, Calhaz-Jorge C, Santos MA, Mauricio JC, Sousa MF. Psychosomatic factors in patients with hyperprolactinemia and/or galactorrhea. Obstet Gynecol. 1980;55:591–5.PubMed
31.
Auriemma RS, Granieri L, Galdiero M, Simeoli C, Perone Y, Vitale P, et al. Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology. 2013;98:299–310.CrossRefPubMed
32.
Brandebourg T, Hugo E, Ben-Jonathan N. Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab. 2007;9:464–76.CrossRefPubMed
33.
Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol. 2006;64:366–70.
34.
dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring). 2011;19:800–5.CrossRefPubMed
35.
Inancli SS, Usluogullari A, Ustu Y, Caner S, Tam AA, Ersoy R, et al. Effect of Cabergolin on insulin sensitivity, inflammation and carotid intimal thickness in patients with prolactinoma. Endocrine. 2013;44:193–9.CrossRefPubMed
36.
Gibson CD, Karmally W, McMahon DJ, Wardlaw SL, Korner J. Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults. Diabetes Obe Metab. 2012;14:335–40.CrossRef
37.
Kamath V, Jones CN, Yip JC, Varasteh BB, Cincotta AH, Reaven GM, et al. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care. 1997;20:1697–701.CrossRefPubMed
38.
Ciresi A, Amato MC, Guarnotta V, Lo Castro F, Giordano C. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol. 2013;79:845–52.CrossRef
Metadata
Title
Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline
Authors
Nazir A. Pala
Bashir A. Laway
Raiz A. Misgar
Rayees A. Dar
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2015
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-015-0094-4

Other articles of this Issue 1/2015

Diabetology & Metabolic Syndrome 1/2015 Go to the issue

Research

Consequences of exercising on ischemia–reperfusion injury in type 2 diabetic Goto-Kakizaki rat hearts: role of the HO/NOS system

Short report

Reduced Slc2a4/GLUT4 expression in subcutaneous adipose tissue of monosodium glutamate obese mice is recovered after atorvastatin treatment

Research

Proportion of Brazilian diabetes patients that achieve treatment goals: implications for better quality of care

Research

Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent

Research

Five-year change of clinical and complications profile of diabetic patients under primary care: a population-based longitudinal study on 127,977 diabetic patients

Research

Health-related quality of life in patients with type 1 diabetes mellitus in the different geographical regions of Brazil: data from the Brazilian Type 1 Diabetes Study Group
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits